类固醇依赖性脏综合征在14岁男孩里图西马布实施后缓解:一个案例报告
Grazyna Waska1, Katarzyna Pielorz-Janiczek2, Andrzej Badeński2
1Internal Medicine, Specialist Hospital No. 1 in Bytom, Bytom, POL.
Cureus
|October 10, 2025
概括
儿童的类固醇依赖性性综合征 (SDNS) 可能具有挑战性. 这一案例表明,Rituximab有效地治疗了一个患有SDNS和焦点细分结核硬化症 (FSGS) 的男孩,导致缓解和药物戒断.
科学领域:
- 儿科脏病学 儿科脏病学
- 免疫学 免疫学 免疫学
- 临床案例研究 临床案例研究
背景情况:
- 类固醇依赖性性综合征 (SDNS) 在儿童中存在管理困难,通常需要长时间的免疫抑制与相关风险.
- 焦点细分质硬化 (FSGS) 是SDNS的常见原因,经常与对标准疗法的反应不佳有关.
- 由于儿童SDNS的慢性免疫抑制,可能会出现生长迟缓和高血压等并发症.
研究的目的:
- 报告一个儿科病例的类固醇依赖性性综合征 (SDNS) 与焦点细分质硬化 (FSGS).
- 评估Rituximab在耐火SDNS病例中实现持续缓解的疗效.
- 要强调并发症的管理和生长激素治疗的潜在作用.
主要方法:
- 一个14岁男孩患有SDNS和FSGS的案例介绍.
- 综述治疗史,包括氨尿素抑制剂,美酸莫菲提尔和随后的利图西马布治疗.
- 临床结果的评估,包括缓解状态,免疫抑制剂的退出和生长参数.
主要成果:
- 在Rituximab治疗后,患者实现了持续缓解和完全停止免疫抑制剂.
- 增长激素治疗是在rituximab后开始的,导致增长和临床状况得到改善.
- 利图西马布在治疗FSGS的复杂儿科SDNS病例方面表现出有效性.
结论:
- 利图西马布为患有耐火性类固醇依赖性脏综合征和FSGS的儿科患者提供了一种可行的治疗选择.
- 仔细监测免疫抑制疗法的不良影响和增长激素等辅助治疗的潜在益处至关重要.
- 这一案例强调了探索替代治疗方法对于挑战性SDNS病例的重要性,这些病例对传统疗法没有反应.
相关概念视频
01:26Nephrotic Syndrome II : Assessment and Medical Management
200
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
200
01:24Nephrotic Syndrome I : Introduction
499
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
499
01:24Nephrotic Syndrome III : Nursing Management
279
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
279
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
488
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
488
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
176
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
176
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
434
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
434